Clinical Trial Detail

NCT ID NCT03769155
Title VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Emory University
Indications

melanoma

Therapies

Nivolumab + Pepinemab

Ipilimumab + Pepinemab

Pepinemab

Ipilimumab + Nivolumab + Pepinemab

Age Groups: adult senior

No variant requirements are available.